VivoSeq
Oncology

Functioning Pancreatic Neuroendocrine Tumor

1

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Functioning Pancreatic Neuroendocrine Tumor is an early-stage landscape with 1 program across 0 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Cabozantinib S-Malate

Exelixis

Approved
No programs

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03375320·298 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)